Active substance
Results for the substance elbasvir+grazoprevir
1 result
About this active substance
Elbasvir and grazoprevir are antiviral medications used in combination to treat chronic hepatitis C (HCV). This combination is effective against several genotypes of the hepatitis C virus, particularly genotypes 1 and 4. The treatment aims to eliminate the virus from the body and prevent liver complications such as cirrhosis or liver cancer.
Elbasvir works by inhibiting the NS5A protein, which is essential for the replication of the hepatitis C virus. Grazoprevir, on the other hand, inhibits the NS3/4A protein, an enzyme necessary for viral processing and multiplication. Together, these medications block the virus's life cycle, reducing the viral load until complete elimination.
This combination is administered as oral tablets, usually once daily, for a duration of 12 to 16 weeks, depending on the stage of the disease and other factors such as cirrhosis. It is important for patients to follow the treatment as prescribed by their doctor to ensure the therapy's success.
Elbasvir and grazoprevir are generally well-tolerated, but side effects such as fatigue, nausea, headache, or elevated liver enzymes may occur. Regular monitoring of liver function and viral load is essential during the course of treatment.
This therapy offers a high cure rate for patients with hepatitis C but does not prevent reinfection. It is important for patients to avoid risk factors such as intravenous drug use or contact with infected blood to prevent a new infection.
Elbasvir works by inhibiting the NS5A protein, which is essential for the replication of the hepatitis C virus. Grazoprevir, on the other hand, inhibits the NS3/4A protein, an enzyme necessary for viral processing and multiplication. Together, these medications block the virus's life cycle, reducing the viral load until complete elimination.
This combination is administered as oral tablets, usually once daily, for a duration of 12 to 16 weeks, depending on the stage of the disease and other factors such as cirrhosis. It is important for patients to follow the treatment as prescribed by their doctor to ensure the therapy's success.
Elbasvir and grazoprevir are generally well-tolerated, but side effects such as fatigue, nausea, headache, or elevated liver enzymes may occur. Regular monitoring of liver function and viral load is essential during the course of treatment.
This therapy offers a high cure rate for patients with hepatitis C but does not prevent reinfection. It is important for patients to avoid risk factors such as intravenous drug use or contact with infected blood to prevent a new infection.